Revumenib
- Generic Name
- Revumenib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47FN6O4S
- CAS Number
- 2169919-21-3
- Unique Ingredient Identifier
- LZ0M43NNF2
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Target Recruit Count
- 415
- Registration Number
- NCT06652438
- Locations
- 🇳🇱
NL-Maastricht-MUMC, Maastricht, Netherlands
🇩🇪DE-Berlin-CAMPUSBENFRANKLIN, Berlin, Germany
🇩🇪DE-Berlin-CAMPUSVIRCHOW, Berlin, Germany
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
- Conditions
- Acute Myeloid LeukemiaChildhood Acute Leukemia of Ambiguous LineageChildhood Acute Lymphoblastic LeukemiaChildhood Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute LeukemiaAcute Leukemia of Ambiguous LineageChildhood Acute Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyOther: Electronic Health Record ReviewOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT06575296
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Revumenib in Combination With 7+3 + Midostaurin in AML
- Conditions
- AML With Gene MutationsAMLLeukemiaAML, AdultAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Richard Stone, MD
- Target Recruit Count
- 22
- Registration Number
- NCT06313437
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT06284486
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06229912
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
- Conditions
- Acute Myeloid Leukemias
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT06226571
- Locations
- 🇺🇸
UCLA Medical Hematology, Burbank, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸AdventHealth Blood & Marrow Transplant Center, Orlando, Florida, United States
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and Biopsy
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 30
- Registration Number
- NCT06222580
- Locations
- 🇺🇸
UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Drug: intrathecal (IT) chemotherapy
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06177067
- Locations
- 🇺🇸
Children's Mercy Hospital of Kansas City, Kansas City, Missouri, United States
🇺🇸Memorial Sloan- Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Expanded Access Program for Revumenib
- Conditions
- Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- 🇺🇸
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Conditions
- Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Multigated Acquisition ScanProcedure: Transthoracic Echocardiography Test
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT05886049
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.